HEAMGEN & GIOSTAR Develop Patented Technology to Manufacture Safe, Abundant Human Red Blood Cells From Stem Cells
Disruptive technology is poised to revolutionize the world’s blood supply chain SAN DIEGO, CA, UNITED STATES, October 6, 2021 /EINPresswire.com/ -- HEAMGEN, Inc. a spinout company of the Global Institute of Stem Cell Therapy and Research (GIOSTAR), has …